Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals reported unaudited Q1 FY26 results: revenue from operations fell to ₹643.26 lakhs from ₹844.34 lakhs a year ago (down ~23.8%). However, net profit surged to ₹241.10 lakhs from ₹16.93 lakhs (up ~14x), driven almost entirely by a one-time gain of ₹283.20 lakhs booked under 'Other Income' from the disposal of its Sanwer Road industrial undertaking in Indore. EPS rose to ₹1.48 from ₹0.10. On the corporate side, the Board approved the appointment of Joshi Sahay & Company as Secretarial Auditors for 5 years, re-appointment of two Independent Directors, redesignated Mr. Ketan Shah as Chairman & Managing Director, constituted a Finance Committee, fixed the 40th AGM for September 27, 2025, and approved shifting the registered office within Indore to 12/B Pologround. The statutory auditor (Maheshwari & Gupta) issued an unmodified limited review report.
Headline profit growth looks spectacular but is essentially a one-time accounting gain from selling a property/unit, not from operations. Core business revenue actually shrank sharply, which is a concern for shareholders looking at sustainable earnings. The registered office shift and director changes are routine governance items with no material pricing impact.